IL151399A0 - Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei - Google Patents
Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nucleiInfo
- Publication number
- IL151399A0 IL151399A0 IL15139901A IL15139901A IL151399A0 IL 151399 A0 IL151399 A0 IL 151399A0 IL 15139901 A IL15139901 A IL 15139901A IL 15139901 A IL15139901 A IL 15139901A IL 151399 A0 IL151399 A0 IL 151399A0
- Authority
- IL
- Israel
- Prior art keywords
- cells
- vector
- interest
- substance
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
Abstract
Amino acid sequences (I) that facilitate penetration of a substance of interest (II) into the inside of a cell and/or its nucleus. (I) can react in vivo with aminoglycans (AG) or can react with AG (sic) and are derived from proteins of human origin. Independent claims are also included for the following: (1) associations of (I) and (II); (2) intracytoplasmic and/or intranuclear transfer vectors consisting of, or containing, at least one (I); (3) eukaryotic cells that contain (I) or the vector of (2) or are transfected with this vector; (4) process for in vitro transfer of (II) into cells; (5) composition (biological, pharmaceutical, cosmetic, nutritional, diagnostic or tracer) containing as active agent a vector of (2) or a cell of (3); (6) diagnostic agent comprising the vector of (2) or the cells of (3); and (7) diagnostic kit containing, in one or more vessels, a predetermined quantity of the composition of (5). ACTIVITY : Antiviral; antibacterial; cytostatic; anti-apoptotic; vasotropic; hemostatic. No supporting data given. MECHANISM OF ACTION : Gene or protein replacement; gene therapy. No supporting data given.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0002621A FR2805821B1 (en) | 2000-03-01 | 2000-03-01 | AMINO ACID SEQUENCES TO FACILITATE THE PENETRATION OF A SUBSTANCE OF INTEREST WITHIN CELLS AND / OR CELL CORES |
PCT/FR2001/000613 WO2001064738A2 (en) | 2000-03-01 | 2001-03-01 | Heparin-binding amino acid sequences derived from human proteins facilitating penetration of a substance of interest into cells and/or cell nuclei |
Publications (1)
Publication Number | Publication Date |
---|---|
IL151399A0 true IL151399A0 (en) | 2003-04-10 |
Family
ID=8847589
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15139901A IL151399A0 (en) | 2000-03-01 | 2001-03-01 | Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei |
IL151399A IL151399A (en) | 2000-03-01 | 2002-08-21 | Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei |
IL190542A IL190542A0 (en) | 2000-03-01 | 2008-03-31 | Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL151399A IL151399A (en) | 2000-03-01 | 2002-08-21 | Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei |
IL190542A IL190542A0 (en) | 2000-03-01 | 2008-03-31 | Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei |
Country Status (13)
Country | Link |
---|---|
EP (2) | EP1259541B1 (en) |
JP (1) | JP4912556B2 (en) |
AT (2) | ATE372346T1 (en) |
AU (1) | AU780785B2 (en) |
BR (1) | BR0108847A (en) |
CA (1) | CA2401613A1 (en) |
DE (2) | DE60137801D1 (en) |
DK (1) | DK1259541T3 (en) |
ES (1) | ES2292567T3 (en) |
FR (1) | FR2805821B1 (en) |
IL (3) | IL151399A0 (en) |
PT (1) | PT1259541E (en) |
WO (1) | WO2001064738A2 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8003595B2 (en) | 2000-03-01 | 2011-08-23 | Cellectis | Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei |
JP4387669B2 (en) | 2000-10-13 | 2009-12-16 | ザイジェン エス.アー. | Intracellular delivery of biological effectors with novel transporter peptide sequences |
US7033597B2 (en) | 2000-10-13 | 2006-04-25 | Université de Lausanne | Intracellular delivery of biological effectors |
US7049286B2 (en) | 2001-08-30 | 2006-05-23 | Diatos, S.A. | Insulin conjugates and methods of use thereof |
FR2841902A1 (en) * | 2002-07-08 | 2004-01-09 | Diatos | CATIONIC LINEAR PEPTIDES HAVING ANTIBACTERIAL AND / OR ANTIFUNGAL PROPERTIES |
EP1512696A1 (en) * | 2003-08-14 | 2005-03-09 | Diatos | Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei |
FR2858772A1 (en) * | 2003-08-14 | 2005-02-18 | Diatos | Antibacterial composition containing cationic peptide and antibiotic, useful particularly for treating infections by Gram-negative species, also new conjugates of peptides and antibiotics |
WO2005018650A2 (en) * | 2003-08-14 | 2005-03-03 | Diatos | Anti-bacterial composition, especially for controlling gram-negative bacteria, comprising a peptide and an advantageously hydrophobic anti-bacterial agent |
WO2007054814A1 (en) | 2005-11-14 | 2007-05-18 | Centre National De La Recherche Scientifique - Cnrs | Inhibitors of parp activity and uses thereof |
EP1797901A1 (en) | 2005-12-16 | 2007-06-20 | Diatos | Cell penetrating peptide conjugates for delivering nucleic acids into cells |
EP1818395A1 (en) * | 2006-02-08 | 2007-08-15 | Diatos | Compositions and methods for treating lysosomal storage diseases |
AU2007232206B2 (en) * | 2006-03-30 | 2013-04-04 | Drais Pharmaceuticals, Inc. | Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same |
EP2172209A1 (en) | 2008-10-03 | 2010-04-07 | Universite Pierre Et Marie Curie | Treatment of mood and anxiety disorders |
EP2539445B1 (en) | 2010-02-26 | 2018-03-21 | Cellectis | Use of endonucleases for inserting transgenes into safe harbor loci |
FR2968662B1 (en) | 2010-12-10 | 2013-11-22 | Roussy Inst Gustave | NOVEL PRE-ACTIVE OXAZAPHOSPHORINE DERIVATIVES, USE AND METHOD OF PREPARATION |
EP2714971A4 (en) * | 2011-05-23 | 2015-01-21 | Phylogica Ltd | Method of determining, identifying or isolating cell-penetrating peptides |
JP6517018B2 (en) * | 2012-02-09 | 2019-05-22 | ヴァー2・ファーマシューティカルズ・アンパルトセルスカブVAR2 Pharmaceuticals ApS | Targeting chondroitin sulfate glycans |
GB201322396D0 (en) | 2013-12-18 | 2014-02-05 | Univ Nottingham | Transduction |
CN112457383B (en) * | 2020-12-16 | 2022-06-17 | 阿南达 | Polypeptide, preparation method and medical application thereof |
AU2022409717A1 (en) | 2021-12-16 | 2024-05-30 | Pags Co., Ltd. | Cell penetrating polypeptides (cpps) and their use in human therapy |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60233099A (en) * | 1984-05-04 | 1985-11-19 | Asahi Chem Ind Co Ltd | Novel peptide |
DK455789D0 (en) * | 1989-09-15 | 1989-09-15 | Symbicom Ab | POLYPEPTIDE |
WO1996008274A2 (en) * | 1994-09-13 | 1996-03-21 | Prizm Pharmaceuticals, Inc. | Conjugates of heparin-binding epidermal growth factor-like growth factor with targeted agents |
FR2736642B1 (en) | 1995-07-10 | 1997-09-12 | Pasteur Institut | IMMUNOVECTORS, IN PARTICULAR ANTIBODIES AND FRAGMENTS OF ANTIBODIES FOR USE IN THE INTRACELLULAR AND INTRANUCLEAR TRANSPORT OF BIOLOGICALLY ACTIVE PRINCIPLES IN PARTICULAR OF HAPTENES, PROTEINS AND NUCLEIC ACIDS |
US6635623B1 (en) * | 1997-06-13 | 2003-10-21 | Baylor College Of Medicine | Lipoproteins as nucleic acid vectors |
FR2766826B1 (en) * | 1997-08-04 | 2001-05-18 | Pasteur Institut | VECTORS DERIVED FROM ANTIBODIES FOR TRANSFERRING SUBSTANCES IN CELLS |
-
2000
- 2000-03-01 FR FR0002621A patent/FR2805821B1/en not_active Expired - Fee Related
-
2001
- 2001-03-01 DE DE60137801T patent/DE60137801D1/en not_active Expired - Fee Related
- 2001-03-01 DK DK01911821T patent/DK1259541T3/en active
- 2001-03-01 ES ES01911821T patent/ES2292567T3/en not_active Expired - Lifetime
- 2001-03-01 EP EP01911821A patent/EP1259541B1/en not_active Expired - Lifetime
- 2001-03-01 IL IL15139901A patent/IL151399A0/en active IP Right Grant
- 2001-03-01 AT AT01911821T patent/ATE372346T1/en active
- 2001-03-01 EP EP04292771A patent/EP1526183B1/en not_active Expired - Lifetime
- 2001-03-01 AU AU40748/01A patent/AU780785B2/en not_active Ceased
- 2001-03-01 DE DE60130324T patent/DE60130324T2/en not_active Expired - Lifetime
- 2001-03-01 WO PCT/FR2001/000613 patent/WO2001064738A2/en active Application Filing
- 2001-03-01 BR BR0108847-5A patent/BR0108847A/en not_active Application Discontinuation
- 2001-03-01 JP JP2001564231A patent/JP4912556B2/en not_active Expired - Fee Related
- 2001-03-01 PT PT01911821T patent/PT1259541E/en unknown
- 2001-03-01 CA CA002401613A patent/CA2401613A1/en not_active Abandoned
- 2001-03-01 AT AT04292771T patent/ATE423849T1/en not_active IP Right Cessation
-
2002
- 2002-08-21 IL IL151399A patent/IL151399A/en not_active IP Right Cessation
-
2008
- 2008-03-31 IL IL190542A patent/IL190542A0/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP4912556B2 (en) | 2012-04-11 |
IL190542A0 (en) | 2008-11-03 |
WO2001064738A3 (en) | 2002-09-06 |
EP1259541B1 (en) | 2007-09-05 |
DE60137801D1 (en) | 2009-04-09 |
EP1526183A3 (en) | 2005-12-07 |
DE60130324T2 (en) | 2008-05-29 |
FR2805821B1 (en) | 2004-01-16 |
BR0108847A (en) | 2003-02-18 |
EP1259541A2 (en) | 2002-11-27 |
DE60130324D1 (en) | 2007-10-18 |
ATE423849T1 (en) | 2009-03-15 |
FR2805821A1 (en) | 2001-09-07 |
CA2401613A1 (en) | 2001-09-07 |
DK1259541T3 (en) | 2008-01-07 |
WO2001064738A2 (en) | 2001-09-07 |
AU4074801A (en) | 2001-09-12 |
JP2003528596A (en) | 2003-09-30 |
EP1526183B1 (en) | 2009-02-25 |
ATE372346T1 (en) | 2007-09-15 |
EP1526183A2 (en) | 2005-04-27 |
ES2292567T3 (en) | 2008-03-16 |
IL151399A (en) | 2008-11-26 |
PT1259541E (en) | 2007-12-17 |
AU780785B2 (en) | 2005-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL190542A0 (en) | Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei | |
GOSPODAROWICZ et al. | Fibroblast and epidermal growth factors are mitogenic agents for cultured granulosa cells of rodent, porcine, and human origin | |
KR101831887B1 (en) | Peptides Having Activities for Hair Growth and Promoting Melanin Synthesis and Uses Thereof | |
KR101791526B1 (en) | Peptides having Hair Growth Activity and Uses Thereof | |
AR006188A1 (en) | "PHARMACEUTICAL COMPOSITION TO INHIBIT SERINPROTEASE ACTIVITY, IN VITRO METHOD TO INHIBIT SERINPROTEASE ACTIVITY AND METHOD TO PREPARE SUCH COMPOSITION". | |
EP1426058A3 (en) | Liquid interferon-beta formulations | |
CA2265252A1 (en) | Angiogenic factor and use thereof in treating cardiovascular disease | |
ZA95137B (en) | Composition containing nucleic acids preparation and use | |
WO2001035932A3 (en) | Sustained drug delivery from structural matrices | |
HK1047129A1 (en) | Sequence-specific dna recombination in eukaryotic cells | |
EP1362917A3 (en) | A fusion protein for use as vector | |
DK1783225T3 (en) | Structural protein from AAV, its preparation and use | |
IL133253A0 (en) | Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them | |
Mattioli et al. | Osteo-regenerative potential of ovarian granulosa cells: an in vitro and in vivo study | |
WO1997026322A3 (en) | Methods and compositions for inhibiting hexokinase | |
IL134593A0 (en) | A cell system for in-vivo expression of an interferon beta protein, pharmaceutical compositions containing the same and methods for the preparation thereof | |
WO2003092598A3 (en) | Treatment for pompe disease | |
IL145403A0 (en) | Fragments of virus protein 2 or 3 of the polyoma virus, use for transporting active ingredients | |
HK1032064A1 (en) | Bile acid salts of metals with physiological action and the use thereof in therapy. | |
WO2004084800A3 (en) | A3 receptor-mediated cardioprotective proteins and therapeutic and diagnostic methods of use | |
WO2002012336A3 (en) | TGF-β THERAPEUTICS, COMPOSITIONS AND METHODS OF USE | |
CN1853609A (en) | Skin-care effectiveness applied by acid fiber mother cell growth factor (FGF-1) | |
UA91488C2 (en) | New class of physiologically active glycoproteins | |
Jaynes | Mueller cell survival and proliferation in response to a retinal pigment epithelial cell-derived factor. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed |